倍他乐克对慢性心力衰竭患者肿瘤坏死因子受体Ⅱ的影响  

Effects of Betaloc on sTNFR-Ⅱ in patients with chronic heart failure

作　　者：黄斌[1] 雷长城[1] 朱翔[1] 

机构地区：[1]南华大学附属第二医院心内科,湖南省衡阳市421001

出　　处：《中国心血管病研究》2008年第2期118-120,共3页Chinese Journal of Cardiovascular Research

摘　　要：目的探讨倍他乐克对慢性心力衰竭患者血清sTNFR-Ⅱ水平治疗前后的影响。方法采用酶联免疫双抗体夹心法测定正常对照组(26例)及慢性心力衷竭患者(60例)血清sTNFR-Ⅱ水平。其中60例心力衰竭患者随机分为常规治疗组(30例)及倍他乐克治疗组(30例),疗程4周,治疗组患者治疗前、后采血测sTNFR-Ⅱ。结果心力衰竭患者治疗前较正常对照组血清sTNFR-Ⅱ水平明显升高,差异有统计学意义[(8.93±4.13)μg/L和(2.34±0.76)μg/L,P<0.05];心力衰竭常规治疗组及倍他乐克组治疗后血清sTN-FR-Ⅱ水平均较治疗前明显降低,差异有统计学意义[(8.85±5.12)μg/L和(4.38±1.76)μg/L,(9.04±4.76)μg/L和(4.67±2.15)μg/L,P<0.05],但两组治疗后血浆STNFR-Ⅱ水平比较差异无统计学意义[(4.38±1.76)μg/L和(4.67±2.15)μg/L,P>0.05]。结论慢性心力衰竭患者血清sTNFR-Ⅱ水平增高,倍他乐克不影响慢性心衰患者血浆sTNFR-Ⅱ水平。Objective To study the effects of Betaloc on sTNFR- Ⅱ in patients with chronic heart failure. Methods We measured the serum level of sTNFR- Ⅱ in 26 cases of control group and the different levels in 60 patients with chronic heart failure before and after treatment with routine drugs or Betaloc. Results The serum levels of sTNFR-Ⅱ in patients with C HF were significantly higher than those of the control group [ （8.93±4.13）μg/L vs （2.34±0.76）μg/L,P〈0.05 ]. After 4 weeks treatment, the serum levels of sTNFR-Ⅱ in patients with CHF were significantly decreased both in routine group and Betaloc group [（8.85±5.12）μg/L vs （4.38±1.76）μg/L, （9.04± 4.76）μg/L vs （4.67±2.15）μg/L, P〈0.05 ]. Compared with the routine group, these was not a significant reduction of the serum level of sTNFR- Ⅱ in Betaloc group after treatment [（4.38±1.76）μg/L vs （4.67±2.15）μg/L,P〉 0.05 ]. Conclusion The serum level of sTNFR- Ⅱ in patients with CHF was significantly high, the treatment of Betaloc could not reduce effectly the serum level of sTNFR-Ⅱ in patients with Chronic heart failure.

关 键 词：倍他乐克 心力衰竭 充血性 受体 肿瘤坏死因子 

分 类 号：R541.61[医药卫生—心血管疾病]